Company
Cizzle Biotechnology Holdings PLC
LON:CIZ
Cizzle Biotechnology is developing a blood test for the early detection of a majority of the different forms of lung cancer. The company is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Cizzle Biotechnology's proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is highly correlated with early stage lung cancer.
16 stories
Cizzle Biotechnology shares simmer as it is revealed that Conduit Pharmaceuticals plans US listing
Diagnostics group Cizzle has a royalty deal with Conduit
Cizzle Biotechnology's cancer test expansion boosts shares
New projects have been initiated by the company which might widen the cancer biomarker utility
Archive
HeiQ higher after its 'climate positive' yarn attracts Hugo Boss and The Lycra Company
A look at the major movers on the London market on Monday
Archive
Michelmersch Brick builds up a good rise as profits set to beat expectations
A look at the major movers on the London market on Thursday
Archive
Hardide rebounds after winning first coating order for power turbine blades
A look at Thursday's major share movers on the London Stock Exchange